Largest biotech by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total liabilities, at CZK 1.82T, ahead of Gilead Sciences (CZK 809.1B) and Biogen (CZK 248.5B). Figures as of 18 Nov 2026, 14:10 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenCZK 1.82T
- Median
- CZK 15.6B
- Combined market value
- CZK 18.87T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | CZK 1.82T | CZK 5.51T | CZK 10,177.49 | 0.95% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | CZK 809.1B | CZK 4.69T | CZK 3,784.03 | 1.60% up | 33% up | ||
| 3 | BiogenBIIB · Health Care | CZK 248.5B | CZK 823.9B | CZK 5,573.81 | 0.34% down | 49% up | ||
| 4 | ModernaMRNA · Health Care | CZK 82B | CZK 1.86T | CZK 4,596.13 | 3.93% down | 755% up | ||
| 5 | BioNTechBNTX · Health Care | CZK 68.2B | CZK 467.6B | CZK 1,886.01 | 0.47% down | 16% down | ||
| 6 | QiagenQGEN · Health Care | CZK 55.6B | CZK 228.3B | CZK 1,105.69 | 0.12% down | 12% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | CZK 55B | CZK 243.2B | CZK 2,132.93 | 0.55% down | 37% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | CZK 30.6B | CZK 373.3B | CZK 3,687.57 | 0.37% up | 20% up | ||
| 9 | argenxARGX · Health Care | CZK 30.2B | CZK 1.32T | CZK 21,058.63 | 0.36% down | 4% up | ||
| 10 | ImmunityBioIBRX · Health Care | CZK 22.3B | CZK 148B | CZK 139.13 | 4.68% up | 193% up | ||
| 11 | RepligenRGEN · Health Care | CZK 18.7B | CZK 230.4B | CZK 3,604.45 | 0.37% down | 5% up | ||
| 12 | Revolution MedicinesRVMD · Health Care | CZK 16.1B | CZK 782.1B | CZK 3,615.79 | 2.50% down | 131% up | ||
| 13 | ExelixisEXEL · Health Care | CZK 15.2B | CZK 371.5B | CZK 1,522.41 | 2.09% up | 63% up | ||
| 14 | Bio-TechneTECH · Health Care | CZK 10.6B | CZK 253.6B | CZK 1,614.20 | 0.22% down | 26% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | CZK 7.6B | CZK 86.6B | CZK 892.33 | 0.54% down | 21% down | ||
| 16 | VaxcytePCVX · Health Care | CZK 7B | CZK 209B | CZK 1,320.17 | 3.59% down | 22% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | CZK 6.4B | CZK 102.5B | CZK 633.19 | 2.22% up | 88% up | ||
| 18 | Kodiak SciencesKOD · Health Care | CZK 4.3B | CZK 140.7B | CZK 2,151.38 | 3.90% down | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | CZK 3.8B | CZK 169.7B | CZK 2,489.20 | 6.63% up | 340% up | ||
| 20 | Kymera TherapeuticsKYMR · Health Care | CZK 3.6B | CZK 230.6B | CZK 2,700.78 | 3.44% down | 87% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | CZK 3.5B | CZK 122.2B | CZK 1,001.90 | 1.21% up | 14% up | ||
| 22 | Krystal BiotechKRYS · Health Care | CZK 2.5B | CZK 196.6B | CZK 6,635.27 | 0.22% up | 46% up | ||
| 23 | ImmunovantIMVT · Health Care | CZK 2.3B | CZK 152.7B | CZK 738.09 | 0.21% down | 43% up | ||
| 24 | CG OncologyCGON · Health Care | CZK 866.6M | CZK 156.7B | CZK 1,754.44 | 6.89% down | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2250 CZK).
Questions and answers
Which biotech rank first by total liabilities?
Amgen (CZK 1.82T), Gilead Sciences (CZK 809.1B) and Biogen (CZK 248.5B) are the top three of the 24 biotech ranked by total liabilities as of 18 Nov 2026, 14:10 UTC.
How many biotech are in this ranking?
24 are ranked by total liabilities.
What are these biotech worth together?
The 24 biotech ranked by total liabilities have a combined market value of CZK 18.87T as of 18 Nov 2026, 14:10 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.